Product Information

Product NameSalmeterol Xinafoate IP/BP/EP/USP
Structure
IUPAC Name(1RS)-1-[4-Hydroxy-3-(hydroxymethyl) phenyl]-2-[[6-(4-phenylbutoxy)hexy]amino]ethanol-1-hydroxy naphtha lene-2-caroxylate

1, 3-Benzenedimethanol, 4-hydroxy- α1-[[[6-(4-phenyl butoxy) hexyl] amino] methyl]-, (±)-, 1-hydroxy-2-naphthalenecarboxylate (salt);

(±)-4-Hydroxy-α1-[[[6-(4-phenylbutoxy) hexyl] amino] methyl]-m-xylene-α, α, ¢-diol 1-hydroxy-2-naphthoate (salt)

CAS No94749-08-3
Molecular FormulaC36H45NO7
Molecular Weight604
AppearanceWhite or almost white powder
SolubilityPractically insoluble in water, soluble in methanol, slightly soluble in anhydrous ethanol, practically insoluble in methylene chloride, Slightly soluble in alcohol, in isopropanol and in chloroform, practically insoluble in water (pH 8), and in saline solution (0.9 %w/w)
Melting Range137°-138°C
Patent StatusProduct patent – Out of patent
Therap.Cat Salmeterol is a long-acting β2 adrenergic receptor agonist (LABA) used in the maintenance and prevention of asthma symptoms and maintenance of chronic obstructive pulmonary disease (COPD) symptoms. Symptoms of bronchospasm include coughing and chest tightness.